Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer

Seung Yoon Lee,JooYeon Jhun,Jin Seok Woo,Kun Hee Lee,Sun-Hee Hwang,Jeonghyeon Moon,Goeun Park,Sun Shim Choi,So Jung Kim,Yoon Ju Jung,Kyo Young Song,Mi-La Cho
DOI: https://doi.org/10.1080/19490976.2023.2300846
IF: 12.2
2024-01-12
Gut Microbes
Abstract:Early detection and surgical treatment are essential to achieve a good outcome in gastric cancer (GC). Stage IV and recurrent GC have a poor prognosis. Therefore, new treatments for GC are needed. We investigated the intestinal microbiome of GC patients and attempted to reverse the immunosuppression of the immune and cancer cells of GC patients through the modulation of microbiome metabolites. We evaluated the levels of programmed death-ligand 1 (PD-L1) and interleukin (IL)-10 in the peripheral blood immunocytes of GC patients. Cancer tissues were obtained from patients who underwent surgical resection of GC, and stained sections of cancer tissues were visualized via confocal microscopy. The intestinal microbiome was analyzed using stool samples of healthy individuals and GC patients. Patient-derived avatar model was developed by injecting peripheral blood mononuclear cells (PBMCs) from advanced GC (AGC) patients into NSG mice, followed by injection of AGS cells. PD-L1 and IL-10 had higher expression levels in immune cells of GC patients than in those of healthy controls. The levels of immunosuppressive factors were increased in the immune and tumor cells of tumor tissues of GC patients. The abundances of Faecalibacterium and Bifidobacterium in the intestinal flora were lower in GC patients than in healthy individuals. Butyrate, a representative microbiome metabolite, suppressed the expression levels of PD-L1 and IL-10 in immune cells. In addition, the PBMCs of AGC patients showed increased levels of immunosuppressive factors in the avatar mouse model. Butyrate inhibited tumor growth in mice. Restoration of the intestinal microbiome and its metabolic functions inhibit tumor growth and reverse the immunosuppression due to increased PD-L1 and IL-10 levels in PBMCs and tumor cells of GC patients.
gastroenterology & hepatology,microbiology
What problem does this paper attempt to address?
The paper aims to address the issue of immunosuppression in gastric cancer (GC) patients and explore the potential role of butyrate in regulating the expression of immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages. Specifically: 1. **Expression of Immunosuppressive Markers**: The study evaluated the levels of immunosuppressive markers PD-L1 and IL-10 in peripheral blood mononuclear cells (PBMCs) and tumor tissues of gastric cancer patients. The results showed that the levels of these markers were significantly higher in advanced gastric cancer (AGC) patients compared to early gastric cancer (EGC) patients. 2. **Changes in Gut Microbiome**: The study found an imbalance in the gut microbiome of gastric cancer patients, particularly a significant reduction in the number of butyrate-producing bacteria such as Faecalibacterium, Collinsella, and Bifidobacterium. 3. **Role of Butyrate**: The study explored the inhibitory effect of butyrate on the expression of PD-L1 and IL-10 in PBMCs of gastric cancer patients. In vitro experiments showed that butyrate could significantly reduce the expression of these immunosuppressive markers and inhibit the proliferation of gastric cancer cells. In vivo experiments further validated the anti-tumor effect of butyrate using a humanized mouse model. In summary, this paper primarily investigated the phenomenon of immunosuppression in gastric cancer patients and its relationship with the gut microbiome, and explored the potential of butyrate as a therapeutic approach.